Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: One-year results from the SYNTAX trial

Catheterization and Cardiovascular Interventions

Volumn 79, Issue 2, 2012, Pages 198-209

  Cohen, David J ^a   Lavelle, Tara A ^b   Van Hout, Ben ^c   Li, Haiyan ^a   Lei, Yang ^a   Robertus, Katherine ^a   Pinto, Duane ^d   Magnuson, Elizabeth A ^a   McGarry, Thomas F ^e   Lucas, Scott K ^f   Horwitz, Phillip A ^g   Henry, Carl A ^h   Serruys, Patrick W ⁱ   Mohr, Friedrich W ^j   Kappetein, A Pieter ⁱ  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Oklahoma Foundation for Cardiovascular Research   (United States)

^f St Anthony Hospital Oklahoma City   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

cost benefit analysis; randomized controlled trial; restenosis; revascularization

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863062154     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23147     Document Type: Article

References (40)

1. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996; 335: 217-225.
2. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): A randomised controlled trial. Lancet 2002; 360: 965-970.
3. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schönberger JP, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F,. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46: 575-581. (Pubitemid 41132680)
4. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, Kapoor JR, Ardehali R, Owens DK, Hlatky MA,. Systematic review: The comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med 2007; 147: 703-716. (Pubitemid 351664467)
5. Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, Granillo G, Hueb WA, Lemos PA, Serruys PW,. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: A meta-analysis with 5-year patient-level data from the ARTS. ERACI-II, MASS-II, and SoS trials. Circulation 2008; 118: 1146-1154.
6. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrie D, Clayton TC, D, Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ,. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: A collaborative analysis of individual patient data from ten randomized trials. Lancet 2009; 373: 1190-1197.
7. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB,. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1997; 336: 92-99. (Pubitemid 27020885)
8. Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King SB,. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 1995; 92: 2831-2840.
9. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA,; Arterial Revascularization Therapies Study Group. Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-1124.
10. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW,. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
11. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP Jr, Zidar JP, Kuntz RE,; SIRIUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the Sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary leisons (SIRIUS) trial. Circulation 2004; 110: 508-514. (Pubitemid 39031165)
12. Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ,; TAXUS-IV Investigators. Cost-effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: Results from the TAXUS-IV trial. J Am Coll Cardiol 2006; 48: 253-261. (Pubitemid 44026660)
13. Groeneveld PW, Greenhut A, Matta MA, Yang F,. The costs of drug-eluting coronary stents among medicare beneficiaries. Am Heart J 2008; 155: 1097-1105.
14. Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr, Mack MJ, van den Brand M, Morel MA, van Es GA, Kleijne J, Koglin J, Russell ME,. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. Am Heart J 2006; 151: 1194-1204. (Pubitemid 44172867)
15. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, StÃhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW,; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972.
16. Drug Topics Red Book. 111th edition. Florence, KY: Thompson Healthcare; 2007.
17. Ashby J,. The accuracy of cost measures derived from medicare cost report data. Hosp Cost Manag Acount 1992; 3: 1-8.
18. Taira DA, Seto TB, Siegrist R, Cosgrove R, Berezin R, Cohen DJ,. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J 2003; 145: 452-458. (Pubitemid 36390491)
19. Kugelmass AD, Cohen DJ, Brown PP, Simon AW, Becker ER, Culler SD,. Hospital resources consumed in treating complications associated with percutaneous coronary interventions. Am J Cardiol 2006; 97: 322-327. (Pubitemid 43133043)
20. Brown PP, Kugelmass AD, Cohen DJ, Reynolds MR, Culler SD, Dee AD, Simon AW,. The frequency and cost of complications associated with coronary artery bypass grafting surgery: Results from the United States Medicare program. Ann Thorac Surg 2008; 85: 1980-1986. (Pubitemid 351695490)
21. Centers for Medicare and Medicaid Services. 100% MEDPAR Inpatient Hospital National Data for Fiscal Year 2007. Short Stay Inpatient Diagnosis Related Groups. Available at: http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/ Downloads/DRG07.pdf. Accessed on August 27, 2010.
22. Mitchell J, Burge R, Lee AJ, McCall NT,. Per Case Prospective Payment for Episodes of Hospital Care. Springfield, VA: U.S. Department of Commerce National Technical Information Service; 1995.
23. Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, Gabriel S, Yusuf S,. CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005; 45: 838-845. (Pubitemid 40342806)
24. Shaw JW, Johnson JA, Coons SJ,. U.S. valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Med Care 2005; 43: 203-220. (Pubitemid 40353904)
25. Weintraub WS, Barnett P, Chen S, Hartigan P, Casperson P, O'Rourke R, Boden WE, Lewis C, Veledar E, Becker E, Culler S, Kolm P, Mahoney EM, Dunbar SB, Deaton C, O'Brien B, Goeree R, Blackhouse G, Nease R, Spertus J, Kaufman S, Teo K,. Economics methods in the clinical outcomes utilizing percutaneous coronary revascularization and aggressive guideline-driven drug evaluation (COURAGE) trial. Am Heart J 2006; 151: 1180-1185. (Pubitemid 43866611)
26. Polsky D, Glick H,. Costing and cost analysis in randomized controlled trials: Caveat emptor. Pharmacoeconomics 2009; 27: 179-188.
27. Efron B, Tibshirani RJ,. An Introduction to the Bootstrap. New York, NY: Chapman and Hall; 1993.
28. Mark DB, Hlatky MA,. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 2002; 106: 516-520. (Pubitemid 34803700)
29. Ryan JW, Cohen DJ,. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation 2006; 114: 1736-1744.
30. Hlatky MA, Boothroyd DB, Melsop KA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD,. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation 2004; 110: 1960-1966. (Pubitemid 39331908)
31. Weintraub WS, Becker ER, Mauldin PD, Culler S, Kosinski AS, King SB,. Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST). Am J Cardiol 2000; 86: 747-752.
32. Sculpher MJ, Seed P, Henderson RA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD,. Health service costs of coronary angioplasty and coronary artery bypass surgery: The Randomised Intervention Treatment of Angina (RITA) trial. The Lancet. 1994; 344: 927-930. (Pubitemid 24295882)
33. Henderson RA, Pocock SJ, Sharp SJ, Nanchahal K, Sculpher MJ, Buxton MJ, Hampton JR,. Long-term results of RITA-1 trial: Clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet 1998; 352: 1419-1425. (Pubitemid 28510875)
34. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA,. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673-681. (Pubitemid 28398701)
35. Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM, Neves JP, Lindeboom W, Backx B,. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004; 109: 1114-1120. (Pubitemid 38332615)
36. Weintraub WS, Mahoney EM, Zhang Z, Chu H, Hutton J, Buxton M, Booth J, Nugara F, Stables RH, Dooley P, Collinson J, Stuteville M, Delahunty N, Wright A, Flather MD, De Cock E,. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart 2004; 90: 782-788. (Pubitemid 38813640)
37. Stroupe KT, Morrison DA, Hlatky MA, Barnett PG, Cao L, Lyttle C, Hynes DM, Henderson WG,. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation 2006; 114: 1251-1257. (Pubitemid 44402050)
38. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FM, Tsiatis AA, Willan AR, Mark DB, Schulman KA,. Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. Am Heart J 2005; 149: 434-443. (Pubitemid 40585405)
39. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC,. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. The Lancet 2010; 375: 201-209.
40. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ,; Spirit IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.